SIP
IMNM icon

Stoneridge Investment Partners’s Immunome IMNM Stock Holding History

Stoneridge Investment Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,174
Closed -$143K – 146
2025
Q3 		$143K Buy
12,174
+620
+5% +$6.17K 0.1% 102
2025
Q2 		$107K Hold
11,554
– – 0.08% 105
2025
Q1 		$78K Hold
11,554
– – 0.07% 100
2024
Q4 		$123K Buy
+11,554
New +$140K 0.04% 113

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Stoneridge Investment Partners's IMNM Position: Q4 2025 in Review

Stoneridge Investment Partners sold out of Immunome (IMNM) in Q4 2025, closing a stake of 12,174 shares — an estimated $143K sold.

Stoneridge Investment Partners first reported a position in IMNM in Q4 2024 and held it in 4 quarters. The position peaked at $143K in Q3 2025. 182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

  • Stoneridge Investment Partners reported no remaining Immunome position as of Q4 2025 after selling out during the quarter.
  • Stoneridge Investment Partners sold 12,174 Immunome shares in Q4 2025, an estimated $143K.
  • Stoneridge Investment Partners first reported a position in Immunome in Q4 2024 and held it in 4 quarters.
  • Stoneridge Investment Partners's Immunome position peaked at $143K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on Stoneridge Investment Partners's 13F filing for Q4 2025, filed 5 Feb 2026.